



## LJMU Research Online

**Kunda, NK, Alfagih, IM, Dennison, SR, Tawfeek, HM, Somavarapu, S, Hutcheon, GA and Saleem, IY**

**Bovine Serum Albumin Adsorbed PGA-co-PDL Nanocarriers for Vaccine Delivery via Dry Powder Inhalation**

<http://researchonline.ljmu.ac.uk/id/eprint/1888/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Kunda, NK, Alfagih, IM, Dennison, SR, Tawfeek, HM, Somavarapu, S, Hutcheon, GA and Saleem, IY (2014) Bovine Serum Albumin Adsorbed PGA-co-PDL Nanocarriers for Vaccine Delivery via Dry Powder Inhalation. *Pharmaceutical Research*. 32 (4). pp. 1341-1353. ISSN 0724-8741**

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk/) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

## **Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation**

Nitesh K Kunda<sup>1</sup>, Iman M Alfagih<sup>1,2</sup>, Sarah Rachel Denisson<sup>3</sup>, Hesham M Tawfeek<sup>4</sup>, Satyanarayana Somavarapu<sup>5</sup>, Gillian A Hutcheon<sup>1</sup>, Imran Y Saleem<sup>1\*</sup>

<sup>1</sup>Formulation and Drug Delivery Research, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom, <sup>2</sup>Department of Pharmaceutics, College of Pharmacy, King Saud University, Saudi Arabia, <sup>3</sup>Research and Innovation, University of Central Lancashire, Preston, United Kingdom, <sup>4</sup>Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, Egypt and <sup>5</sup>Department of Pharmaceutics, School of Pharmacy, University College London, London, United Kingdom.

\*Address correspondence to this author at the School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, James Parson Building, Byrom Street, Liverpool, L3 3AF, UK; Tel: +44(0)151 231 2265; Fax: +44(0)151 231 2170; E-mail: [I.Saleem@ljmu.ac.uk](mailto:I.Saleem@ljmu.ac.uk)

## **ABBREVIATIONS**

|            |   |
|------------|---|
| APCs       | Antigen presenting cells                              |
| BSA        | Bovine serum albumin                                  |
| DCs        | Dendritic cells                                       |
| DoE        | Design of experiment                                  |
| LN         | Lymph node  |
| NPs        | Nanoparticles   |
| NCMPs      | Nanocomposite microparticles                          |
| PGA-co-PDL | poly(glycerol adipate-co- $\omega$ -pentadecalactone) |
| PLA        | polylactide or poly-L-lactic acid                     |
| PLGA       | poly lactic-co-glycolic-acid                          |
| PVA        | polyvinyl alcohol                                     |
| SD         | Spray-drying  |

## 1. Introduction

Vaccination refers to induction of an immune response using antigens coupled with adjuvants for generating a protective immunity against plausible future infections [1,2]. Traditional vaccines are often administered via the parenteral route requiring infrastructure such as cold-chain, sterilized water for reconstitution of dry powder vaccines and trained medical personnel. Lack of these facilities in low and middle income countries (LMIC) is leading to many eligible children and adults not getting vaccinated [3]. Moreover, the majority of the potential vaccines in development employ purified subunits or recombinant proteins that are often poorly immunogenic thus needing adjuvants and effective delivery systems to generate an optimal immune response [1,2]. To address these issues, particulate delivery systems and non-invasive routes of delivery are being investigated. The pulmonary route has gained significant attention for delivery of vaccines as it is one of the main entry portals for pathogens, and can address some of the challenges such as invasiveness, cold-chain requirement, and stability of the antigen by delivering the antigen as a dry powder [3].

Biodegradable polymeric nanoparticles (NPs) have gained significant attention and are largely being explored as delivery vehicles for delivery of peptides, proteins, antigens, DNA etc. [3–5]. These polymers offer controlled or sustained drug release, biocompatibility with surrounding cells and tissues, degrade into low molecular weight non-toxic products and act as adjuvants helping in generating cellular and humoral immune responses [1,3,6]. In this current investigation we aim to use poly(glycerol adipate-co- $\omega$ -pentadecalactone), PGA-co-PDL, a biodegradable polyester polymer, that has extensively been studied by our group for delivery of both small molecule and model drugs (dexamethasone phosphate, ibuprofen, sodium fluorescein), and large molecule drugs ( $\alpha$ -chymotrypsin, DNase I) [7–11].

In these biodegradable polymeric nanoparticulate formulations, the vaccine antigens (i.e. proteins, peptides etc.) are either adsorbed onto the surface or encapsulated within the particles [3]. Encapsulated antigens are protected by polymeric nanoparticles and their release can be modified by tailoring the properties of the polymers. Adsorbed antigen, however, offers enhanced stability and activity over the encapsulated antigen by avoiding contact with organic solvents employed during particle preparation steps [12–14].

Recent strategies for effective vaccine delivery have been to target the dendritic cells (DCs), the true professional antigen presenting cells (APCs) [15]. DCs have the exceptional ability to internalize, and in lymph nodes (LNs) they process and present antigens through major histocompatibility complex (MHC) class I and II pathways thereby activating naïve T-cells resulting in induction of a strong immune response [3,15,16]. A study conducted by Manolova *et al* indicates the importance of particle size in determining the uptake by DCs, where it was shown that upon intracutaneous injection of polystyrene beads of varying sizes, large particles (500–2000 nm) associated with DCs from the site of injection whereas small particles (20–200 nm) drained freely to the LNs and were present in LN resident DCs [16]. In addition, Kim *et al* have also shown that uptake of 200 nm sized NPs by bone marrow DCs to be more than that of 30 nm sized NPs [17]. Furthermore, Foged *et al* has shown that particle size of 500 nm or below were preferred and have shown fast and efficient up take by human DCs derived from blood [18]. The above literature suggests that smaller particles of 200 to 500 nm could effectively be up taken by DCs and thus generates a stronger immune response compared to vaccine alone. However, these studies cannot be directly compared to lung DCs but owing to the lack of information on the effect of NP size on uptake by lung DCs the same can be assumed.

In this study, the Taguchi L<sub>18</sub> orthogonal array design of experiment (DoE) was used to optimize the formulation parameters to achieve NPs (~150 nm) for targeting the lung DCs. The literature suggests that factors such as molecular weight (MW) of the polymer, organic solvent, aqueous phase, sonication time and stirrer speed have an influence on the size of the resultant NPs [19–21] and these were evaluated using the experimental design.

As a dry powder, the nanosized particles cannot be directly used for inhalation as their size is too small and it is expected that majority of the inhaled dose will be exhaled depositing very minimal doses in the lung [22]. Thus, these nanoparticles are formulated into nanocomposite microparticles (NCMPs) using additives such as lactose [22], L-leucine [23,24], trehalose[25], mannitol [25] by various manufacturing techniques such as freeze drying, spray drying, spray-freeze drying or supercritical fluid technologies [3,26]. The NCMPs in the size range of 1 to 5 µm in diameter are reported to be deposited in the respirable airways and periphery of the lung [27]. The additives used to form NCMPs dissolve upon encountering the respiratory environment thereby releasing the NPs [28].

In this project, we aim to produce PGA-co-PDL NPs of optimum size to be effectively taken up by the DCs, surface adsorb a model protein, bovine serum albumin (BSA) and formulate into nanocomposite microparticles (NCMPs) using L-leucine as a carrier for delivery via dry powder inhalation.

## **2. Materials and Methods**

### **2.1. Materials**

Dichloromethane (DCM) was purchased from BDH, laboratory supplies, UK. Novozyme 435 (a lipase from *Candida antarctica* immobilized on a microporous acrylic resin) was purchased from Biocatalytics, USA. Acetonitrile (HPLC grade), [albumin tagged with fluorescein isothiocyanate \(FITC-BSA\)](#), bovine serum albumin (BSA, MW 67 KDa), phosphate buffered

saline (PBS, pH 7.4) tablets, poly(vinyl alcohol) (PVA, MW 9–10 KDa, 80%), trifluoroacetic acid (TFA, HPLC grade), RPMI-1640 medium with L-glutamine and NaHCO<sub>3</sub>, thiazoly blue tetrazolium bromide (MTT), tween 80<sup>®</sup> and  $\omega$ -pentadecalactone were obtained from Sigma-Aldrich, UK. L-leucine (L-leu) was purchased from BioUltra, Sigma, UK. 75 cm<sup>2</sup>/tissue culture flasks with vented cap, 96-well flat bottom plates, acetone, antibiotic/ antimycotic solution (100X), dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific, UK. Divinyladipate was obtained from Fluorochem, UK. Fetal calf serum (FCS) heat inactivated was purchased from Biosera UK. poly(glycerol adipate-co- $\omega$ -pentadecalactone) (PGA-co-PDL, MW of 14.7, 24.0 KDa) was synthesized in our laboratory at LJMU and micro BCA<sup>™</sup> protein assay kit was purchased from Thermo Scientific, UK. A549 cell line was purchased from ATCC. 16HBE14o- cells were obtained from Dr Dieter Gruenert from the California Pacific Medical Center, University of California San Francisco, USA.

## **2.2. Polymer Synthesis**

The PGA-co-PDL polymer of MW of 14.7, 24.0 KDa was synthesized in our laboratory via enzyme catalyzed co-polymerization of three monomers as described by Thompson et al. [29]. The synthesized linear polyester was characterized by gel permeation chromatography, GPC (Viscotek TDA Model 300 using OmniSEC3 operating software), pre-calibrated with polystyrene standards (polystyrene standards kit, Supelco, USA), and <sup>1</sup>H-NMR spectroscopy (Bruker AVANCE 300 MHz, Inverse probe with B-ACS 60, Auto sampler with gradient chemming) as described by Thompson et al. [29].

## **2.3. Preparation of Nanoparticles**

The PGA-co-PDL NPs were fabricated using a modified oil-in-water (o/w) single emulsion solvent evaporation method [30]. Briefly, 200 mg PGA-co-PDL polymer (MW 14.7 KDa) [\(and Nile Red, NR 0.5 mg for characterization of protein adsorption onto the surface of PGA-co-](#)

[PDL via confocal microscopy](#)) was dissolved in 2 ml DCM and probe sonicated (20 microns amplitude) upon addition to 5 ml of 10% w/v poly(vinyl alcohol) (PVA) (1<sup>st</sup> aqueous solution) for 2 min to obtain an emulsion. This whole process was performed using ice. This was immediately added drop wise to 20 ml of 2<sup>nd</sup> aqueous solution (0.75% w/v PVA) under magnetic stirring at a speed of 500 RPM. The whole mixture was left stirring at room temperature for 3 h to facilitate the evaporation of DCM. [The particle size, PDI and zeta-potential were then characterised as mentioned in section 2.6.](#) The NP suspensions were collected by centrifugation (78,000g, 40 min, 4°C) and surface adsorbed with protein as indicated in section 2.54.

#### **2.4. Taguchi Design of Experiment (DoE)**

In order to evaluate the influence of formulation parameters and minimize the number of experiments, Taguchi DoE being appropriate to study large number of factors, was employed through Minitab<sup>®</sup> 16 Statistical Software. Seven factors, namely, [polymer](#) MW, organic solvent, internal aqueous phase concentration and volume, sonication time, stirrer speed and external aqueous phase concentration were evaluated by constructing and using L<sub>18</sub> orthogonal array design with 1 factor, MW, at 2 levels and remaining 6 factors at 3 levels (Table I).

The design was applied to identify the significant factors that would affect the size of PGA-co-PDL NPs. Optimum conditions were indicated by high signal-to-noise (S/N) ratios, where signal factor (S) is the outcome, the particle size, and noise factors (N) are parameters such as humidity, temperature, experience of the experimenter etc. A greater S/N ratio corresponds to minimum variance of the outcome, the particle size i.e. a better performance. In other words, the experimental parameter having the least variability is the optimum condition [31]. The optimization of size was carried out using the Taguchi's 'smaller-is-better' criterion i.e. to get the outcome, the particle size, to an ideal target of zero or as small as possible.

## 2.5. Protein Adsorption

NP suspension (equivalent to 10 mg i.e. 1.25 ml of suspension) was centrifuged (78,000g, 40 min, 4°C) and the resultant pellet was resuspended in vials containing 4 ml of BSA [\(or FITC-BSA for characterization of protein adsorption onto the surface of PGA-co-PDL via confocal microscopy\)](#), for 1 h, at different ratios of 100: 4, 100: 10 and 100: 20 (NPs: BSA) corresponding to 100, 250 and 500 µg/ml BSA concentrations, respectively. The resulting suspension (for 100: 20) was left rotating for 30 min, 1, 2 and 24 h at 20 RPM on a HulaMixer™ Sample Mixer (Life Technologies, Invitrogen, UK). After respective time points, the protein adsorbed NP suspensions were centrifuged and the supernatant analysed for protein content using micro BCA protein assay kit. The amount of BSA adsorbed per milligram of NPs (n=3) was calculated using eq. 1:

$$\text{Adsorption } (\mu\text{g per mg of NPs}) = \frac{(\text{Initial protein conc} - \text{Supernatant protein conc})}{\text{Amount of NPs}} \quad (1)$$

[The particle size and PDI were then characterised as mentioned in section 2.6.](#)

## 2.6. Nanoparticle Characterization

Particle size, poly dispersity index (PDI, a number between 0 and 1 describing the homogeneity of the sample) and zeta-potential were measured by laser diffraction using a laser particle size analyser (Zetasizer Nano ZS, Malvern Instruments Ltd, UK). [For NPs suspension, an aliquot of 100 µl of the NP suspension was diluted with 5 ml of deionized water and for NP suspensions with and without BSA adsorption, 2 mg of NPs were resuspended in 5 mL of deionized water,](#) loaded into a cuvette and the measurements were recorded at 25°C (n=3).

## 2.7. Nanocomposite Microparticles

Spray-drying was employed to incorporate the NPs into nanocomposite microparticles (NCMPs) using L-leucine as a carrier, and at nanoparticles-to-carrier ratio of 1:1.5 w/w. Blank NPs, BSA-loaded NPs or [FITC-BSA-loaded NR NPs](#) were dispersed in 20 ml water with L-leucine dissolved and spray-dried using a Büchi B-290 mini spray-dryer (Büchi Labortechnik, Flawil, Switzerland) with a nozzle atomizer, and nozzle orifice diameter of 0.7 mm. The spray-drying was performed at a feed rate 10%, an atomizing air flow of 400 L/h, aspirator capacity of 100% and an inlet temperature of 100°C (outlet temperature approximately 45 - 47°C). The dry particles (PGA-co-PDL/L-leu NCMPs) were separated from the air stream using a high-performance cyclone (Büchi Labortechnik), and the dry particles were collected and stored in desiccator until further use.

## **2.8. Nanocomposite microparticles Characterization**

### **2.8.1. Yield**

The dry powder yield was determined as the difference in the weight of the sample vial before and after product collection. The weight difference was compared to the initial total dry mass and the yield in % (w/w) was calculated (n=3).

### **2.8.2. Particle Size and Morphology**

To confirm the recovery of NPs from NCMPs with an appropriate size range for cellular uptake, particle size and PDI of NPs following re-dispersion of blank and loaded NCMPs in water were measured. The measurements were recorded as mentioned in section 2.6, where 5 mg of NCMPs were dispersed in 2 ml of deionized water then loaded into a cuvette and the measurements were recorded at 25°C (n=3).

Spray dried PGA-co-PDL/L-Leu NCMPs samples were mounted on aluminium stubs (pin stubs, 13 mm) layered with a sticky conductive carbon tab and coated with palladium (10-15

nm) using a sputter coater (EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min). The particles were then visualized using scanning electron microscopy (FEI Quanta™ 200 ESEM, Holland).

### **2.8.3. Confocal Laser Scanning Microscopy**

FITC-BSA-loaded NR NPs spray-dried into NCMPs were observed under confocal microscope to visualise the adsorption of BSA onto the NPs. Briefly, a Zeiss 510 Meta laser scanning microscope mounted on a Axiovert 200 M BP computer-controlled inverted microscope was used to obtain the confocal images. A few milligrams of spray-dried NCMPs were placed in a single well of 8-well chambered (Fisher Scientific, UK) and imaged by excitation at a wavelength of 488 nm (green channel for FITC-BSA), 543 nm (red channel for Nile Red NPs) and a Plan Neofluar 63×/0.30 numerical aperture (NA) objective lens. Image analysis was carried out using the Zeiss LSM software.

### **2.8.3.2.8.4. Protein Quantification by HPLC**

An HPLC method was developed to quantify the amount of BSA present in NCMPs. The chromatographic conditions were as follows: HPLC system Agilent 1100 series (Santa Clara, CA, USA) equipped with a column (Aeris 3.6 µm C4 200A Wide Pore 4.6mm i.d. x 150 mm length), security cartridge of the same material (Phenomenex, UK) and software for data processing; mobile phase was composed of (A) 0.1% TFA in water and (B) 0.1% TFA in acetonitrile with a gradient flow of A/B from 80:20 to 35:65 in 25 min, post-time 6 min; flow rate of 0.8 ml/min; injection volume of 100 µl; run temperature 40°C; UV detection at 214 nm and BSA retention time of 14.4 min. BSA calibration curve was prepared by accurate dilution of a previously prepared stock solution (1 mg/ml) in HPLC water and PBS (pH 7.4) to obtain the following concentrations: 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 µg/ml of BSA (n = 9, R<sup>2</sup> = 0.999). All solutions used in the process were filtered using 0.45 µm filters prior to use. Limit

of Detection (LOD) in water – 1.98 µg/ml, PBS – 1.48 µg/ml and Limit of Quantification (LOQ) in water – 3.24 µg/ml, PBS – 3.20 µg/ml.

#### **2.8.4.2.8.5. In vitro Release Studies**

BSA adsorbed PGA-co-PDL/L-leu NCMPs (20 mg) were transferred into eppendorfs and dispersed in 2 ml of PBS, pH 7.4. The samples were incubated at 37°C and left rotating for 48 h at 20 RPM on a HulaMixer™ Sample Mixer (Life Technologies, Invitrogen, UK). At pre-determined time intervals up to 48 h, the samples were centrifuged (accuSpin Micro 17, Fisher Scientific, UK) at 17,000g for 30 min and 1 ml of the supernatant removed and replaced with fresh medium. The supernatant was analysed using the HPLC method as mentioned above. Each experiment was repeated in triplicate and the result was the mean value of three different samples (n=3). The percentage cumulative BSA released was calculated using eq. 2:

$$\% \text{ Cumulative BSA released} = \frac{\text{Cumulative BSA released}}{\text{BSA loaded}} \times 100 \quad (2)$$

#### **2.8.5.2.8.6. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)**

The stability primary structure of BSA released from within the NCMPs after spray-drying was determined by SDS-PAGE. SDS-PAGE was performed on CVS10D omniPAGE vertical gel electrophoresis system (Geneflow Limited, UK) with 9% stacking gel prepared using ProtoGel stacking buffer (Geneflow Limited, UK) containing 0.4% of SDS. Protein molecular weight markers in the range 10–220 KDa (Geneflow Limited, UK) and BSA were used as control. The protein loading buffer blue (2X) (0.5M Tris-HCl (pH 6.8), 4.4% (w/v) SDS, 20% (v/v) Glycerol, 2% (v/v) 2- mercaptoethanol and bromphenol blue in distilled/deionised water) was added to the samples in 1:1 (v/v) buffer-to-sample ratio. After loading the samples (25 µl sample per well), the gel was run for approximately 2.5 h at a voltage of 100 V with Tris-

Glycine-SDS PAGE buffer (10X) (Geneflow Limited, UK) containing 0.25M Tris base, 1.92M glycine and 1% (w/v) SDS. The gel was stained with [colloidal coomassie blue and then destained in distilled water overnight](#). An image of the gel was scanned on a gel scanner (GS-700 Imaging Densitometer, Bio-Rad) equipped with Quantity One software.

#### **2.8.6-2.8.7. Circular Dichroism (CD)**

[The secondary structure of standard BSA \(control\), BSA supernatant \(after 1 h adsorption followed by centrifugation\) and BSA released from NPs after 48 h was determined by measuring circular dichroism spectra. All CD experiments were performed using a J-815 spectropolarimeter \(Jasco, UK\) at 20 °C as previously described \[32\]. Five scans per sample using a 10 mm path-length cell were performed over a wavelength range 260 to 180 nm at a data pitch of 0.5 nm, band width of 1 nm and a scan speed 50 nm min<sup>-1</sup>. Far-UV CD spectra were collated for standard BSA, supernatant BSA in HPLC grade water, BSA released in PBS for 48 h. For all spectra, the baseline acquired in the absence of sample was subtracted \[33\]. The secondary structure of the samples was estimated using using the CDSSTR method \[34\] from the DichroWeb server \[34–36\].](#)

#### **2.8.7-2.8.8. *In vitro* Aerosolization Studies**

The Next Generation Impactor (NGI) was employed to assess the aerosol performance of spray-dried NCMPs. The BSA adsorbed NCMPs were weighed (4 capsules each corresponding to 12.5 mg Spray-dried, SD, powder equivalent to 5 mg of NPs) and manually loaded into the hydroxypropyl methylcellulose, HPMC, capsule (size 3), and placed in a Cyclohaler® (Teva pharma). The samples were drawn through the induction port into the NGI using a pump (Copley Scientific, Nottingham, UK) operated at a flow rate of 60 L/min for 4 s. The plates were coated with 1% tween 80: acetone solution and samples collected using a known volume of distilled water, and left on a roller-shaker for 48 h for the BSA to be released from NCMPs.

The samples were centrifuged using an ultracentrifuge (as mentioned in section 2.3) and the supernatants analysed using HPLC method as mentioned above to determine the amount of BSA deposited. The Fine Particle Fraction (FPF, %) was determined as the fraction of emitted dose deposited in the NGI with  $d_{ae} < 4.46 \mu\text{m}$ , the mass median aerodynamic diameter (MMAD) was calculated from log-probability analysis, and the fine particle dose (FPD) was expressed as the mass of drug deposited in the NGI  $d_{ae} < 4.46 \mu\text{m}$  (n=3).

#### **2.8.8.2.8.9. Cell Viability Study**

The *in vitro* cytotoxicity of the empty PGA-co-PDL/L-leu NCMPs was evaluated using the MTT assay. The adenocarcinomic human alveolar basal epithelial cell line, A549 (passage no. 32) or 16HBE14o- cells (passage no. 32) were seeded in 100  $\mu\text{l}$  ( $2.5 \times 10^5$  cells/ml) of RPMI-1640 medium supplemented with 10% fetal calf serum/1% Antibiotic/Antimycotic solution (complete medium) in 96-well plates and placed in an incubator at 37°C for 24 h supplemented with 5% CO<sub>2</sub>. Then, 100  $\mu\text{l}$  of freshly prepared NCMP dispersions in complete medium were added to the wells to an appropriate concentration (0 - 2.5 mg/ml) (n = 3), and 10% dimethyl sulfoxide (DMSO) as a positive control. The formulations were assayed for toxicity over 24 h of incubation, followed by the addition of 40  $\mu\text{l}$  of a 5 mg/ml MTT solution in PBS to each well. After 2 h of incubation at 37°C, the culture medium was gently removed and replaced by 100  $\mu\text{l}$  of dimethyl sulfoxide in order to dissolve the formazan crystals. The absorbance of the solubilised dye, which correlates with the number of living cells, was measured at 570 nm using a plate reader (Molecular Devices, SpectraMAX 190). The percentage of viable cells in each well was calculated as the absorbance ratio between nanoparticle-treated and untreated control cells.

### **2.9. Statistical Analysis**

All statistical analysis was performed using Minitab<sup>®</sup> 16 Statistical Software. One-way analysis of variance (ANOVA) using Minitab<sup>®</sup> 16 Statistical Software with the Tukey's comparison was employed for comparing the formulations with each other. Statistically significant differences were assumed when  $p < 0.05$ . All values are expressed as their mean  $\pm$  standard deviation.

### **3. Results**

#### **3.1. Polymer Synthesis**

The synthesized PGA-co-PDL co-polymer (monomer ratio, 1:1:1) was a white powder with a molecular weight of 14.7, 24.0 KDa for 6 h, 24 h as determined by the GPC. The integration pattern of the co-polymer was confirmed by <sup>1</sup>H-NMR spectra, ( $\delta$ H CDCl<sub>3</sub>, 300 MHz): 1.34 (s, 22 H, H-g), 1.65 (m, 8 H, H-e, e', h), 2.32 (m, 6 H, H-d, d', i), 4.05 (q)-4.18 (m) (6 H, H-a, b, c, f), 5.2 (s, H, H-j).

#### **3.2. Taguchi Design of Experiment (DoE)**

The Taguchi design was applied in this study to identify the significant factors that would influence the size of PGA-co-PDL NPs. Considering seven factors (1 factor at 2 levels and 6 factors at 3 levels) to be investigated, non-usage of an experimental design would have resulted in  $2 \times 3^6 = 1458$  individual experiments which would be an arduous task and inefficient. The Taguchi L<sub>18</sub> orthogonal array design resulted in 18 runs to be performed to yield the optimum conditions for each factor in achieving the smallest PGA-co-PDL NP size. Table II illustrates the structure of the L<sub>18</sub> orthogonal array, the corresponding results and S/N ratios.

The results obtained from 18 runs indicated particle sizes ranging from  $138.7 \pm 6.4$  (run 3) to  $459.4 \pm 69.5$  (run 11). Figure 1 shows the mean S/N graph of the particle size for each parameter level. The parameter with the largest range and corresponding rank (indicates the relative

importance compared to other parameters) was considered as the critical factor affecting that particle size.

Analysis of the particle sizes of 18 runs using the Taguchi's 'smaller-is-better' criterion in Minitab® 16 Statistical Software, the optimum conditions inferred from the range, rank and the S/N response graph were A1B3C3D3E2F2G2. The optimum formulation made using these conditions yielded NPs with a size of  $128.50 \pm 6.57$  nm lower than the minimum size of  $138.7 \pm 6.4$  nm obtained using run 3, PDI of  $0.07 \pm 0.03$  and zeta-potential of  $-10.2 \pm 3.75$  mV.

### 3.3. Protein Adsorption

Figure 2a shows the amount of BSA adsorbed per mg of NPs for different concentrations of BSA loaded. The average adsorption of BSA,  $\mu\text{g}$  per mg of NPs, increased significantly from 100: 4 (NP: BSA) loading concentration ( $4.75 \pm 0.39$ ), 100: 10 ( $6.59 \pm 1.28$ ) to 100: 20 ( $10.23 \pm 1.87$ ) ( $p < 0.05$ , ANOVA/Tukey's comparison).

Figure 2b shows the amount of BSA adsorbed in  $\mu\text{g}$  per mg of NPs at different time points for 100: 20 (NP: BSA) loading concentration. The average adsorption increased significantly from 30 min ( $1.84 \pm 0.82$ ) to 1 h ( $10.23 \pm 1.87$ ) ( $p < 0.05$ , ANOVA/Tukey's comparison) with no significant difference beyond 1 h compared to that of 2 h ( $8.76 \pm 0.34$ ) and 24 h ( $8.95 \pm 0.39$ ) ( $p > 0.05$ , ANOVA/Tukey's comparison) indicating maximum adsorption at 1 h.

Table III lists the particle size and PDI of PGA-co-PDL NPs with and without BSA adsorption. As seen, there is a significant increase ( $p < 0.05$ , ANOVA/Tukey's comparison) in size which is attributed to the adsorption of BSA onto NPs as confirmed using confocal microscopy (section 3.4.3).

### 3.4. Nanocomposite Microparticles Characterization

### 3.4.1. Yield

A reasonable yield of spray drying,  $40.36 \pm 1.80$  % for the empty PGA-co-PDL NCMPs and  $42.35 \pm 3.17$  % for the BSA adsorbed PGA-co-PDL/L-leu NCMPs was obtained.

### 3.4.2. Particle Size and Morphology

The size of NPs after recovery from spray-dried blank NCMPs in water was  $210.03 \pm 15.57$  nm and PDI  $0.355 \pm 0.067$  and for that of BSA loaded NCMPs was  $222.46 \pm 2.17$  nm and PDI  $0.36 \pm 0.008$ , which is in the range of 200 to 500 nm for uptake by dendritic cells (DCs) [16-18].

The shape and surface texture of NCMPs were investigated using scanning electron microscopy (Fig. 3). Photomicrographs of NCMPs showed irregular and corrugated microparticles.

### 3.4.3. Confocal Laser Scanning Microscopy

CLSM was used to observe the interaction of BSA with NPs. The microscopic images in Fig. 4a (split view) and 4b (orthogonal view) shows the spray-dried NCMPs containing the fluorescent nanoparticles (red, labelled using NR dye) adsorbed with FITC-BSA (green). The image shows that FITC-BSA was evidently only present where the NPs were present, indicating their association. Moreover, the increase in size observed after adsorption also confirms the adsorption of BSA onto PGA-co-PDL NPs (Table III).

### 3.4.3.3.4.4. In vitro Release Studies

*In vitro* release studies were performed on NCMPs and reported as cumulative percentage BSA released over time (Fig. 54). An initial burst release of  $30.15 \pm 2.33$  % (BSA) was observed followed by ~~rapid continuous release that continued for~~ up to 5 h, with BSA release of

86.07±0.95 %. After this time period, a slow continuous release of BSA was observed with release of 95.15±1.08 % over 48 h, indicating an excellent release profile for the PGA-co-PDL/L-leu NCMPs.

#### **3.4.4.3.4.5. Protein Stability (SDS-PAGE and CD)**

The primary structure of BSA released from the NCMPs was investigated using SDS-PAGE analysis. Figure 56 reveals identical bands for the standard BSA and desorbed BSA from NCMPs without any newly noticeable bands of high and low molecular BSA.

The secondary structure analysis was performed using CD spectral data. Figure 7a and 7b shows the structure of standard BSA, BSA supernatant and BSA released. In Fig 7a, the CD spectra show minima at 221 - 222 and 209 – 210 nm and maximum at about 195 nm for both samples, which is characteristic of  $\alpha$ -helical structure. Further structural analysis showed that the predominant structure of the peptide was helical displaying 51 and 62.5% helicity respectively (Table IV). Moreover, the experimental data obtained for the standard BSA are in good agreement with previous reports [37]. Figure 7b shows that BSA released displayed double minima at 208 and 222 nm and further spectra analysis indicated this sample adopted a reduced level helical conformation (circa 36% helical) (Table IV). Comparing the CD results of BSA released with that of standard BSA, the content of  $\alpha$ -helix decreases by 15%, the  $\beta$ -sheet content increases by 8.9%, the turns content increases by 1%, and the random coils' content increases by 3% respectively.

#### **3.4.5.3.4.6. In vitro Aerosolization Studies**

The deposition data obtained from spray-dried formulations displayed a FPD of 112.87±33.64  $\mu$ g, FPF of 76.95±5.61 % and MMAD of 1.21±0.67  $\mu$ m. This suggest that the BSA adsorbed PGA-co-PDL/L-leu NCMPs were capable of delivering efficient BSA to the lungs, and are

expected to deposit the majority of the emitted dose to the bronchial-alveolar region of the lungs [3].

#### **3.4.6.3.4.7. Cell Viability Study**

The non-adsorbed PGA-co-PDL NCMPs appear to be well tolerated by both the cell lines, with a cell viability of  $87.01 \pm 14.11$  % (A549 cell line) and  $106.04 \pm 21.14$  % (16HBE14o- cell line) (Fig. 68) at 1.25 mg/ml concentration after 24 h exposure indicating a good toxicity profile without any significant difference in cell viability between particle loadings. This provides an indication about the feasibility of using PGA-co-PDL polymers as safe carriers for pulmonary drug delivery.

## **4. Discussion**

### **4.1. Nanoparticle Preparation and Characterization**

The PGA-co-PDL NPs were prepared using a modified oil-in-water (o/w) single emulsion solvent evaporation method [30]. The results of 18 runs, suggested by Taguchi's  $L_{18}$  orthogonal array, resulted in NPs of size  $< 150$  nm. However, this increases to about 200 - 300 nm after centrifugation and BSA adsorption. This according to the literature suggests ~~free draining of NPs to the LN and also an~~ effective uptake by DCs [16–18]. The effects of each factor are discussed in detail below:

Factor D, PVA concentration (range = 3.17, rank = 1), is the most important factor affecting the particle size. The S/N ratios at three levels indicated that particle size almost linearly decreased with increase in surfactant concentration from 2.5 to 10% w/v (S/N ratio,  $r^2 = 0.997$ ). The particle size decreases because at lower concentrations there is inadequate amount of surfactant to cover all the surfaces of PGA-co-PDL NPs [38]. The uncovered NPs then tend to aggregate until a point where there is adequate amount of surfactant to cover the total surface

area of the aggregated NPs, and form a stable system leading to larger particles. However, with an increase in surfactant concentration it was possible to efficiently cover all the surfaces of NPs thereby stabilizing the system avoiding aggregation and resulting in smaller PGA-co-PDL NPs [38]. This effect of decrease in particle size with an increase in surfactant concentration, PVA, was also observed by Mitra and Lin [39].

The S/N ratios of factor A, molecular weight of the polymer (range = 2.19, rank = 3), at two levels, suggested a directly proportional relationship with MW of polymer, i.e. the particle size decreases with a decrease in the MW of the polymer. This can also be evident from the lower particle size measurements observed using 14.7 KDa MW polymer (runs 1-9) relative to 24 KDa MW polymer (runs 10-18). As the MW of polymer increases, the viscosity of the polymeric solution also increases, thereby imposing difficulty in breaking them into smaller emulsion droplets when compared to lower MW polymer requiring lower efficiency to breakdown under similar conditions. This increase in size of the particles has also been observed by others and is reported to be associated with high MW polymers [5,40,41]

The S/N ratios of factor B, volume of organic solvent (DCM, range = 2.32, rank = 2), at three levels indicated that particle size almost linearly decreased with increase in volume from 1 to 2 ml (S/N ratio,  $r^2 = 0.999$ ). This decrease in particle size is attributed to the ~~has been related to an increase in decrease in~~ viscositiesy of the polymer solution (keeping the amount and MW of polymer constant). This makes it easier to break into smaller emulsion droplets resulting in a decreased particle size as explained above. This effect could also be observed with factor C, volume of 1<sup>st</sup> aqueous phase (range = 1.23, rank = 5), where a decrease in volume increased the viscosity thereby resulting in an increase in particle size.

The S/N ratios for factor E, sonication time (range = 2.09, rank = 4), did not follow any particular trend; however, the 2<sup>nd</sup> level was found to be the optimum for achieving smaller

particle size. The S/N ratios for parameters F, sonication time stirrer speed (the speed at which the magnetic bar was rotating for evaporation of DCM in the external phase) and G, 2<sup>nd</sup> PVA concentration have a low range of 0.34 and 0.18 respectively indicating that they have a minimal influence over the size of nanoparticles produced. Therefore, the optimum conditions inferred from the S/N response graph were A1B3C3D3E2F2G2 producing NPs of  $128.50 \pm 6.57$  nm in size result in NPs of size suitable for cellular uptake into DC as established in the literature [16–18,42,43].

The adsorption of BSA onto NPs is expected to be mainly driven by hydrophobic, electrostatic (ionic) interactions and hydrogen bonding [44]. However, in this study as the NPs, evident from zeta-potential values, are negatively charged ( $-10.2 \pm 3.75$  mV) and BSA in water is also highly negatively charged [45] suggesting that the electrostatic interactions are minimal and that the adsorption process is dominated by the hydrophobic interactions and hydrogen bonding. The BSA adsorption onto NPs increased with an increase in NP: BSA ratio from 100: 4 to 100: 20, which was expected as the amount of BSA available for adsorption increased. Figure 2 (b) suggests that the surface of NPs was saturated with BSA after 1 h suggesting maximum adsorption with 100: 20 (NP: BSA) BSA loading concentration.

#### **4.2. Nanocomposite Microparticles Characterization**

NCMPs were produced by spray-drying using L-leucine as a carrier and a dispersibility enhancer. The SEM pictures (Fig. 3) show irregular or wrinkled surface which is due to an excessive build-up of vapour pressure during water evaporation in the spray drying process and occurs with hydrophobic amino acids, such as L-Leucine [8,46,47].

The release profile shows more than 90% of the BSA released within 48 h this is because of weaker hydrophobic interactions between BSA and NPs compared to the strong ionic interactions. Moreover, the identical bands observed for BSA standard and desorbed BSA from

NCMPs suggests that protein has maintained its primary structure and was neither degraded nor affected by the adsorption and spray drying procedure.

The secondary structure of BSA in the formulation was analysed using CD spectroscopy, a valuable technique in analysing the protein structure [32]. The BSA released samples confirms the presence of  $\alpha$ -helix and  $\beta$ -sheets though decreased compared to standard BSA. However, in protein secondary structure, it is believed that the  $\beta$ -sheet structure is sometimes observed as a special  $\alpha$ -helix only with two amino acid residues through stretching resulting from the breakage of hydrogen bond [37,48].

The FPF value ( $76.95 \pm 5.61\%$ ) suggests an excellent aerosolization performance and deep lung deposition profile. The surface activity of the relatively strong hydrophobic alkyl side chain of L-leucine accumulating at the particle surface during spray drying reduces the surface free energy of the dry powder and cohesive inter-particulate interactions and this might be a plausible explanation for the enhanced dispersibility [8,24]. In addition, the dispersibility enhancing property of L-leucine resulting from its corrugated surface that reduces the contact points between particles leads to an improved aerosolization characteristic of powders [23,47,49]. Similar reports have also demonstrated the enhanced aerosol performance with L-leucine containing formulations [23,47,49,50]. Moreover, the MMAD values show an efficient delivery of NCMPs containing BSA to the deep lungs mainly to the bronchial-alveolar region [3]. A study by Todoroff *et al* have shown that more intense specific immune responses could be achieved by targeting the antigen to the deep lungs than to the upper airways [51]. Also, Menzel *et al* have shown that upon inhalation of Pneumovax<sup>®</sup>, a pneumococcal polysaccharide vaccine, by healthy volunteers the vaccine deposited in the alveolar region displayed increased serum antibody levels compared to that deposited in the larger airways [52]. Thus, this deposition to the deep lungs may generate stronger immune responses.

The NGI data (~~MMAD of 1.21±0.67 μm~~) suggests a deposition mainly in the bronchial-alveolar region of the lungs[3], thus the cell viability studies were performed on A549 cell line (adenocarcinomic human alveolar basal epithelial cells) and 16HBE14o- cell line (human bronchial epithelial cells). The results show that both the cell lines were tolerant to the NCMPs up to 1.25 mg/ml concentration encouraging further investigation in animals.

## 5. Conclusions

PGA-co-PDL nanoparticles of appropriate size to target DCs were successfully produced using Taguchi L18 orthogonal array DoE. BSA adsorption onto NPs in the ratio of 100: 20 (NPs: BSA) for 1 h at room temperature produced the maximum adsorption of BSA (10.23±1.87 μg of protein per mg of NPs). The BSA adsorbed NPs were successfully spray-dried using L-leucine into NCMPs producing a yield of 42.35±3.17% and the NCMPs had irregular and corrugated morphology. The BSA released from the NCMPs was shown to be maintaining its structure under SDS-PAGE and CD analysis. Moreover, FPF of 76.49±6.26 % and MMAD of 1.21±0.67 μm values indicate deep lung deposition with NCMPs showing a low toxicity profile. This study suggests that PGA-co-PDL NCMPs could be used as a novel carrier for pulmonary vaccine delivery.

## Acknowledgements

We would like to thank Dr Mark Murphy (Liverpool John Moores University, Liverpool, UK) for his help with confocal microscopy studies

## 6. References

1. Leleux J, Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. *Advanced healthcare materials*. 2013;2:72–94.
2. Akagi T, Baba M, Akashi M. Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. 2012;31–64.
3. Kunda N, Somavarapu S, Gordon S, Hutcheon G, Saleem I. Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery. *Pharmaceutical Research*. 2013;30:325–41.
4. Amorij JP, Saluja V, Petersen AH, Hinrichs WLJ, Huckriede A, Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. *Vaccine*. 2007;25:8707–17.
5. Thomas C, Rawat A, Hope-Weeks L, Ahsan F. Aerosolized PLA and PLGA Nanoparticles Enhance Humoral, Mucosal and Cytokine Responses to Hepatitis B Vaccine. *Molecular Pharmaceutics*. 2010;8:405–15.
6. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. *Advanced Drug Delivery Reviews*. 2003;55:329–47.
7. Kallinteri P, Higgins S, Hutcheon GA, St. Pourçain CB, Garnett MC. Novel Functionalized Biodegradable Polymers for Nanoparticle Drug Delivery Systems. *Biomacromolecules*. 2005;6:1885–94.
8. Tawfeek H, Khidr S, Samy E, Ahmed S, Murphy M, Mohammed A, et al. Poly(Glycerol Adipate-co- $\omega$ -Pentadecalactone) Spray-Dried Microparticles as Sustained Release Carriers for Pulmonary Delivery. *Pharmaceutical Research*. 2011;28:2086–97.
9. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S, et al. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers. *International Journal of Pharmaceutics*. 2013;441:611–9.
10. Gaskell EE, Hobbs G, Rostron C, Hutcheon GA. Encapsulation and release of  $\alpha$ -chymotrypsin from poly(glycerol adipate-co- $\omega$ -pentadecalactone) microparticles. *Journal of Microencapsulation*. 2008;25:187–95.
11. Thompson CJ, Hansford D, Higgins S, Rostron C, Hutcheon GA, Munday DL. Evaluation of ibuprofen-loaded microspheres prepared from novel copolyesters. *International Journal of Pharmaceutics*. 2007;329:53–61.
12. Duncan G, Jess TJ, Mohamed F, Price NC, Kelly SM, Van der Walle CF. The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. *Journal of Controlled Release*. 2005;110:34–48.

13. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. *Advanced Drug Delivery Reviews*. 2008;60:915–28.
14. Saleem IY, Vordermeier M, Barralet JE, Coombes AGA. Improving peptide-based assays to differentiate between vaccination and *Mycobacterium bovis* infection in cattle using nanoparticle carriers for adsorbed antigens. *Journal of Controlled Release*. 2005;102:551–61.
15. Sou T, Meeusen EN, De Veer M, Morton DA V, Kaminskas LM, McIntosh MP. New developments in dry powder pulmonary vaccine delivery. *Trends in Biotechnology*. 2011;29:191–8.
16. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. *European Journal of Immunology*. 2008;38:1404–13.
17. Kim H, Uto T, Akagi T, Baba M, Akashi M. Amphiphilic Poly(Amino Acid) Nanoparticles Induce Size-Dependent Dendritic Cell Maturation. *Advanced Functional Materials*. 2010;20:3925–31.
18. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. *International Journal of Pharmaceutics*. 2005;298:315–22.
19. Bilati U, Allémann E, Doelker E. Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method—processing and formulation issues for enhanced entrapment efficiency. *Journal of Microencapsulation*. 2005;22:205–14.
20. Li X, Deng X, Yuan M, Xiong C, Huang Z, Zhang Y, et al. Investigation on process parameters involved in preparation of poly-dl-lactide-poly(ethylene glycol) microspheres containing *Leptospira Interrogans* antigens. *International Journal of Pharmaceutics*. 1999;178:245–55.
21. Sanad R, Abdel Malak N, El-Bayoomy T, AA B. Preparation and characterization of oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreens efficacy: SPF and UVA-PF. *Drug Discoveries & Therapeutics*. 2010;4:472–83.
22. Stevanovic M, Uskokovic D. Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins. *Current Nanoscience*. 2009. p. 1–14.
23. Li H-Y, Seville PC, Williamson IJ, Birchall JC. The use of amino acids to enhance the aerosolization of spray-dried powders for pulmonary gene therapy. *The Journal of Gene Medicine*. 2005;7:343–53.
24. Seville PC, Learoyd TP, Li H-Y, Williamson IJ, Birchall JC. Amino acid-modified spray-dried powders with enhanced aerosolization properties for pulmonary drug delivery. *Powder Technology*. 2007;178:40–50.
25. Bosquillon C, Lombry C, Pr eat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. *Journal of Controlled Release*. 2001;70:329–39.

26. Al-fagih IM, Alanazi FK, Hutcheon GA, Saleem I. Recent Advances Using Supercritical Fluid Techniques for Pulmonary Administration of Macromolecules via Dry Powder Formulations. *Drug Delivery Letters*. 2011;1:128–34.
27. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. *Medicinal Research Reviews*. 2009;29:196–212.
28. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *Journal of Controlled Release*. 2001;70:1–20.
29. Thompson CJ, Hansford D, Higgins S, Hutcheon GA, Rostron C, Munday DL. Enzymatic synthesis and evaluation of new novel  $\omega$ -pentadecalactone polymers for the production of biodegradable microspheres. *Journal of Microencapsulation*. 2006;23:213–26.
30. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. *Nanomedicine : nanotechnology, biology, and medicine*. 2006;2:8–21.
31. Kim K Do, Kim SH, Kim HT. Applying the Taguchi method to the optimization for the synthesis of TiO<sub>2</sub> nanoparticles by hydrolysis of TEOT in micelles. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 2005;254:99–105.
32. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. *Nat. Protocols*. 2007;1:2876–90.
33. Henzler Wildman KA, Lee D-K, Ramamoorthy A. Mechanism of Lipid Bilayer Disruption by the Human Antimicrobial Peptide, LL-37†. *Biochemistry*. 2003;42:6545–58.
34. Whitmore L, Woollett B, Miles AJ, Janes RW, Wallace BA. The protein circular dichroism data bank, a Web-based site for access to circular dichroism spectroscopic data. *Structure (London, England : 1993)*. 2010;18:1267–9.
35. Whitmore L, Wallace BA. Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases . *Biopolymers*. 2008;89:392–400.
36. Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Research*. 2004;32 W668–W673.
37. Zhang J, Ma X, Guo Y, Yang L, Shen Q, Wang H, et al. Size-controllable preparation of bovine serum albumin-conjugated PbS nanoparticles. *Materials Chemistry and Physics*. 2010;119:112–7.
38. Douglas SJ, Illum L, Davis SS. Particle size and size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. II. Influence of stabilizers. *Journal of Colloid and Interface Science*. 1985;103:154–63.
39. Mitra A, Lin S. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. *The Journal of Pharmacy and Pharmacology*. 2003;55:895–902.

40. Jalil R, Nixon JR. Microencapsulation using poly (L-lactic Acid) III: Effect of polymer molecular weight on the microcapsule properties. *Journal of Microencapsulation*. 1990;7:41–52.
41. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN V. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. *Journal of Controlled Release*. 2007;119:77–85.
42. Joshi V, Geary S, Salem A. Biodegradable Particles as Vaccine Delivery Systems: Size Matters. *The AAPS Journal*. 2013;15:85–94.
43. Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. *Journal of Controlled Release*. 2010;141:93–100.
44. Yoon J-Y, Kim J-H, Kim W-S. The relationship of interaction forces in the protein adsorption onto polymeric microspheres. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 1999;153:413–9.
45. Regev O, Khalfin R, Zussman E, Cohen Y. About the albumin structure in solution and related electro-spinnability issues. *International Journal of Biological Macromolecules*. 2010;47:261–5.
46. Li H-Y, Neill H, Innocent R, Seville P, Williamson I, Birchall JC. Enhanced Dispersibility and Deposition of Spray-dried Powders for Pulmonary Gene Therapy. *Journal of Drug Targeting*. 2003;11:425–32.
47. Sou T, Kaminskis LM, Nguyen T-H, Carlberg R, McIntosh MP, Morton DA V. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. *European Journal of Pharmaceutics and Biopharmaceutics*. 2013;83:234–43.
48. Yang L, Guo Y, Ma X, Hu Z, Zhu S, Zhang X, et al. Cooperativity between pepsin and crystallization of calcium carbonate in distilled water. *Journal of Inorganic Biochemistry*. 2003;93:197–203.
49. Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. *International Journal of Pharmaceutics*. 2011;409:156–63.
50. Najafabadi AR, Gilani K, Barghi M, Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolization behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. *International Journal of Pharmaceutics*. 2004;285:97–108.
51. Todoroff J, Ucakar B, Inglese M, Vandermarliere S, Fillee C, Renauld J-C, et al. Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. *European Journal of Pharmaceutics and Biopharmaceutics*. 2013; 84(1):40-8.

52. Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. *Vaccine*. 2005;23:5113–9.

**Table I** Taguchi's Experimental Design L<sub>18</sub> for producing PGA-co-PDL nanoparticles

| Levels                             | Units | 1    | 2    | 3   |
|------------------------------------|-------|------|------|-----|
| A - MW of Polymer                  | KDa   | 14.7 | 24.0 | -   |
| B - Org Sol (DCM)                  | ml    | 1    | 1.5  | 2   |
| C - Aq. Vol (PVA)                  | ml    | 3    | 4    | 5   |
| D - 1 <sup>st</sup> Aq. Conc (PVA) | % w/v | 2.5  | 5    | 10  |
| E - Sonication Time                | min   | 1    | 2    | 5   |
| F - Stirrer Speed                  | RPM   | 400  | 500  | 600 |
| G - 2 <sup>nd</sup> Aq. Conc (PVA) | % w/v | 0.5  | 0.75 | 1   |

**Table II** Structure of Taguchi's  $L_{18}$  orthogonal array, corresponding particle size and S/N ratios*(Mean $\pm$ SD, n=6)*

| Runs   | Parameters |   |   |   |   |   |   | Particle Size (nm) | PDI              | S/N Ratio (dB) |
|--------|------------|---|---|---|---|---|---|--------------------|------------------|----------------|
|        | A          | B | C | D | E | F | G |                    |                  |                |
| Run 1  | 1          | 1 | 1 | 1 | 1 | 1 | 1 | 315.5 $\pm$ 6.90   | 0.151 $\pm$ 0.05 | -49.979        |
| Run 2  | 1          | 1 | 2 | 2 | 2 | 2 | 2 | 186.5 $\pm$ 4.30   | 0.097 $\pm$ 0.03 | -45.412        |
| Run 3  | 1          | 1 | 3 | 3 | 3 | 3 | 3 | 138.7 $\pm$ 6.40   | 0.093 $\pm$ 0.01 | -42.843        |
| Run 4  | 1          | 2 | 1 | 1 | 2 | 2 | 3 | 210.1 $\pm$ 18.7   | 0.116 $\pm$ 0.04 | -46.449        |
| Run 5  | 1          | 2 | 2 | 2 | 3 | 3 | 1 | 208.7 $\pm$ 49.9   | 0.123 $\pm$ 0.06 | -46.389        |
| Run 6  | 1          | 2 | 3 | 3 | 1 | 1 | 2 | 182.0 $\pm$ 3.20   | 0.075 $\pm$ 0.04 | -45.199        |
| Run 7  | 1          | 3 | 1 | 2 | 1 | 3 | 2 | 192.9 $\pm$ 9.30   | 0.077 $\pm$ 0.04 | -45.705        |
| Run 8  | 1          | 3 | 2 | 3 | 2 | 1 | 3 | 149.3 $\pm$ 2.50   | 0.075 $\pm$ 0.01 | -43.481        |
| Run 9  | 1          | 3 | 3 | 1 | 3 | 2 | 1 | 192.9 $\pm$ 23.0   | 0.050 $\pm$ 0.03 | -45.704        |
| Run 10 | 2          | 1 | 1 | 3 | 3 | 2 | 2 | 269.1 $\pm$ 68.9   | 0.205 $\pm$ 0.04 | -48.598        |
| Run 11 | 2          | 1 | 2 | 1 | 1 | 3 | 3 | 459.4 $\pm$ 69.5   | 0.233 $\pm$ 0.02 | -53.243        |
| Run 12 | 2          | 1 | 3 | 2 | 2 | 1 | 1 | 242.5 $\pm$ 19.1   | 0.188 $\pm$ 0.06 | -47.694        |
| Run 13 | 2          | 2 | 1 | 2 | 3 | 1 | 3 | 253.2 $\pm$ 47.3   | 0.155 $\pm$ 0.10 | -48.069        |
| Run 14 | 2          | 2 | 2 | 3 | 1 | 2 | 1 | 217.3 $\pm$ 18.9   | 0.116 $\pm$ 0.01 | -46.742        |
| Run 15 | 2          | 2 | 3 | 1 | 2 | 3 | 2 | 240.5 $\pm$ 35.1   | 0.133 $\pm$ 0.05 | -47.622        |
| Run 16 | 2          | 3 | 1 | 3 | 2 | 3 | 1 | 169.3 $\pm$ 7.60   | 0.144 $\pm$ 0.04 | -44.573        |
| Run 17 | 2          | 3 | 2 | 1 | 3 | 1 | 2 | 235.9 $\pm$ 29.6   | 0.119 $\pm$ 0.08 | -47.453        |
| Run 18 | 2          | 3 | 3 | 2 | 1 | 2 | 3 | 221.7 $\pm$ 11.0   | 0.150 $\pm$ 0.04 | -46.915        |

A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc (PVA), E - Sonication time, F - Stirrer Speed and G - 2nd Aq. conc (PVA)

**Table III** Particle size and PDI of PGA-co-PDL nanoparticles without and with BSA adsorption

|                    | NP suspension       | Without BSA adsorption | With BSA adsorption     |
|--------------------|---------------------|------------------------|-------------------------|
| Particle Size (nm) | $128.50 \pm 6.57^a$ | $203.9 \pm 2.55^{b*}$  | $299.03 \pm 32.02^{c*}$ |
| PDI                | $0.070 \pm 0.030$   | $0.205 \pm 0.007$      | $0.322 \pm 0.060$       |

<sup>a</sup> NPs characterised immediately after preparation without centrifugation, <sup>b</sup> NPs characterised after centrifugation but without adsorption of BSA, <sup>c</sup> NPs characterised after centrifugation and BSA adsorption, \*  $p < 0.05$ , ANOVA/Tukey's comparison

**Table IV** The percentages of the secondary structures of standard, supernatant and released BSA samples

| Sample          | Helix            | Strand           | Turns          | Unordered      |
|-----------------|------------------|------------------|----------------|----------------|
| Standard BSA    | $51 \pm 0.007$   | $21.1 \pm 0.07$  | $6.0 \pm 0.01$ | $18 \pm 0.007$ |
| Supernatant BSA | $62.5 \pm 0.035$ | $22.0 \pm 0.021$ | $5.5 \pm 0.05$ | $9.5 \pm 0.06$ |
| Released BSA    | $36.0 \pm 0$     | $30.0 \pm 0$     | $7.0 \pm 0$    | $21 \pm 0.007$ |

The content and level of secondary structure elements in the peptide was calculated from spectral data using the DichroWeb server software as described in Methods

## Legends to Figures

**Fig. 1** Mean S/N graph for particle size response. Letters (A–E) denote the experimental parameters and numeric values denote the parameter levels ( $\diamond$  indicates maximum S/N value) (*Mean* $\pm$ *SD*, *n*=6); Note: A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc (PVA), E - Sonication time, F - Stirrer Speed and G - 2nd Aq. conc (PVA)

**Fig. 2** Amount of BSA adsorbed per mg of NPs at different (a) BSA loading concentrations (NP: BSA) and (b) time points for 100: 20 (NP: BSA) BSA loading concentration, \* is  $p < 0.5$ , \*\* is  $p < 0.05$ , ANOVA/Tukey's comparison (*Mean* $\pm$ *SD*, *n*=3)

**Fig. 3** SEM pictures of PGA-co-PDL/L-Leu Nanocomposite Microparticles (a) 5  $\mu\text{m}$  and (b) 2  $\mu\text{m}$


**Fig. 4** Confocal microscopic image of spray-dried microparticles containing the fluorescent nanoparticles (red, labelled using Nile red dye) adsorbed with FITC-BSA (green) (a) Split view and (b) Orthogonal view

**Fig. 5** In vitro release profiles for BSA adsorbed PGA-co-PDL/L-leu NCMPs in phosphate buffer saline, pH 7.4 (*Mean* $\pm$ *SD*, *n*=3)


**Fig. 6** SDS-PAGE of Lane 1: molecular weight standards, broad range (Bio-Rad Laboratories, Hercules CA, USA), Lane 2, 3: BSA standards, Lane 4, 5, 6: Desorbed BSA from PGA-co-PDL/L-leu NCMPs after 24 h

**Fig. 7** CD spectra of (a) standard BSA (grey) and supernatant BSA (black) and (b) standard BSA (grey) and BSA released (black)



**Fig. 8** A549 & 16HBE14o- cell viability measured by MTT assay after 24 h exposure to PGA-co-PDL NCMPs (*Mean* $\pm$ *SD*, *n*=3)




**Fig 1**




**Fig 2**




**Fig 3**





**Fig 4**




**Fig 5**



**Fig 6**



**Fig 7**



**Fig 8**

